Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocular Therapeutix Inc.

www.ocutx.com

Latest From Ocular Therapeutix Inc.

Eye On The Prize: Drug Delivery Advances To Fuel Ophthalmic Drug Market

The global market for ophthalmic drugs is expected to hit $30.5bn by 2020, fueled in part by the rise in age-related eye conditions like glaucoma, dry eye and macular degeneration. However, there is still an unmet demand for technologies that can deliver these drugs effectively and over a sustained period. This article discusses what the challenges are to developing effective ocular drug delivery systems and highlights several innovative technologies in the pipeline, designed to overcome the limitations of current ophthalmic therapies and potentially accelerate growth of the market.

Ophthalmology Market Intelligence

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Complete Response Letters Regulation

Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade

Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.

Manufacturing Quality

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

The latest drug development news and highlights from our US FDA Performance Tracker.

Regulation Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • I-Therapeutix Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ocular Therapeutix Inc.
  • Senior Management
  • Amar Sawhney, PhD, Pres. & CEO
    Andy Hurley, Chief Commercial Officer
    Peter Jarrett, PhD, CSO
    Michael Goldstein, MD, CMO
  • Contact Info
  • Ocular Therapeutix Inc.
    Phone: (781) 357-4000
    36 Crosby Dr.
    Ste. 105
    Bedford, MA 01730
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register